Futura Medical (AIM:FUM) Appoints Interim CEO Amid Strategic Business Review

Futura Medical plc (AIM:FUM)has confirmed the appointment of Alex Duggan to its Board of Directors as interim Chief Executive Officer, following completion of all necessary due diligence and regulatory procedures. The appointment was initially announced on 8 July 2025 as part of a broader …

Team Kalkine | 08 August 2025

Berenberg Reaffirms Buy Rating on Hikma Pharmaceuticals with AUD 52.75 Price Target

Hikma Pharmaceuticals PLC (LSE: HIK.L), the multinational pharmaceutical group headquartered in the United Kingdom, has received a fresh endorsement from equity research houseBerenberg. AnalystVictoria Lamberthas reaffirmed herBuyrecommendation on the stock, assigning a price target ofAUD 52.75— representing a significant46.29% potential upsidefrom the current trading …

Sonal Goyal | 08 August 2025

Smith+Nephew (LSE:SN) Reports Growth in H1 Profit and Maintains FY25 Guidance, Shares Jump

Smith+Nephew plc (LSE:SN, NYSE:SNN),a global medical technology company, has released results for the six months ended 28 June 2025, reporting increases in trading profit, cash generation, and earnings per share. Underlying revenue grew 5.0% in the first half, with reported revenue rising 4.7%, reflecting …

Team Kalkine | 05 August 2025

Kooth Secures Triple BUY Ratings with Analysts Forecasting Over 200% Share Price Upside

Kooth Plc (LSE:KOO), a pioneering provider of digital mental health solutions, has received a wave of optimism from the market asthree leading analysts – Stifel Europe, Canaccord Genuity, and Berenberg – reaffirmed BUY ratings

Sonal Goyal | 30 July 2025

AstraZeneca (LON:AZN) H1FY25 Revenue Up 11%, EPS Rises 17%, US Expansion Planned

Highlights

Team Kalkine | 29 July 2025

AstraZeneca Commits $50 Billion to U.S. Expansion, Boosting Pharma Jobs and Innovation

AstraZeneca to invest $50 billion in U.S. R&D and manufacturing by 2030.

Sonal Goyal | 22 July 2025

Craneware Delivers Positive FY25 Results, Analysts Reaffirms ‘Buy’ Rating with 19% Upside

Craneware reported a 12% YoY increase in adjusted EBITDA to over $65 million in FY25, with revenue rising 9% to $205.7 million, surpassing market expectations.

Sonal Goyal | 18 July 2025

AstraZeneca Earns Buy Rating with 28% Upside Potential on Regulatory Wins and Encouraging Pipeline

Recent EU and U.S. approvals for Imfinzi and Datopotamab Deruxtecan bolster the company’s oncology portfolio.

Team Kalkine | 10 July 2025

BSF Enterprise (LSE:BSFA) Signs Exclusive Global IP Agreement for LiQD Cornea Technology

BSF Enterprise PLC (LSE:BSFA), a UK-based biotechnology company focused on tissue-engineered materials, announced on 10 July 2025 that its wholly owned subsidiary, Kerato Limited, has entered into an exclusive worldwide option agreement with Université de Montréal. The agreement grants Kerato the global rights to …

Team Kalkine | 10 July 2025

Aptamer Group Raises AUD 3.8 Million via Share Placing to Support Growth and Licensing Pipeline

Highlights

Team Kalkine | 04 July 2025

Healthcare

Futura Medical (AIM:FUM) Appoints Interim CEO Amid Strategic Business Review

Berenberg Reaffirms Buy Rating on Hikma Pharmaceuticals with AUD 52.75 Price Target

Smith+Nephew (LSE:SN) Reports Growth in H1 Profit and Maintains FY25 Guidance, Shares Jump

Kooth Secures Triple BUY Ratings with Analysts Forecasting Over 200% Share Price Upside

AstraZeneca (LON:AZN) H1FY25 Revenue Up 11%, EPS Rises 17%, US Expansion Planned

AstraZeneca Commits $50 Billion to U.S. Expansion, Boosting Pharma Jobs and Innovation

Craneware Delivers Positive FY25 Results, Analysts Reaffirms ‘Buy’ Rating with 19% Upside

AstraZeneca Earns Buy Rating with 28% Upside Potential on Regulatory Wins and Encouraging Pipeline

BSF Enterprise (LSE:BSFA) Signs Exclusive Global IP Agreement for LiQD Cornea Technology

Aptamer Group Raises AUD 3.8 Million via Share Placing to Support Growth and Licensing Pipeline

Latest News

FORT Shares Climb 5%: Is Fort Technology Starting a New Momentum Run?

GFR Shares Climb 3%: Is Greenfire Resources Heating Up With Energy Buyers?

FTG Stock Climbs 4%: Is Firan Technology Group Back in Growth Mode?

FISH Stock Climbs 4%: Is Sailfish Royalty’s Precious-Metals Exposure Attracting Buyers?

GAU Shares Gain 3%: Is Galiano Gold Joining the Precious-Metals Rally?

EOG Stock Rises 5%: Is Eco Atlantic Back in Energy Investors’ Sights?